Basel III intends to improve banks’ resilience to financial crises. This report provides constructive arguments that if the EU incorporates social and environmental criteria in the new standards, banks’ risk management and decision making processes, it will more effectively promote financial stability and be more capable of addressing diverse challenges banks are facing now and in the future. Moreover, such regulation would stimulate the financial sector to contribute to a more ecologically and socially sustainable, economically just and peaceful world. Sustainability criteria in capital requirements will encourage banks to better align their operations with economic, social and environmental needs. Regulators and supervisors who develop regulatory and supervisory tools should improve their understanding of sustainability risks.
read more lessrelated content
How Big Tech is becoming the Government
Will a new EU law help to achieve the climate change targets?
In order to meet the climate targets of the Paris Agreement and encourage more environmentally friendly investments, a new EU law establishes clear EU definitions of what ‘green’ actually is. This EU Taxonomy Regulation wants…
The EU taxonomy
Time to start caring about cobalt
Large insurers do not tackle abuse in cobalt mining
The nine largest insurance groups in the Netherlands (Achmea, Aegon, Allianz, ASR, CZ, Menzis, NN Group, VGZ and Vivat) do not do enough to prevent or tackle serious human rights violations in the cobalt sector….
Crash Course
A new webinar series entitled ‘Crash Course’ will be launched in the second week of June. SOMO is one of the partners in this platform that is designed to open up debate on how we…
The earnings model of the pharmaceutical industry needs to be overhauled
We Can’t Afford Big Pharma’s Greed
Private gains we can ill afford
SOMO reveals the financialisation of the pharmaceutical industry and the potentially deadly costs
Research by SOMO into the world’s 27 largest pharmaceutical companies shows that over the past eighteen years, the sector has shifted its focus from being a pharmaceutical producer to an investment industry. The research undermines…